A Phase 3 interventional study of Ivermectin Cream, 1% and Placebo/Vehicle cream in Moderate to Severe Papulopustular Rosacea, sponsored by Actavis Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-02.
Sponsored by Actavis Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 145 studies in Rosacea with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Rosacea · United States.
Among the 145 studies in Rosacea with a site in United States, this one is the 14th largest by enrollment of the 137 interventional ones that give a count, is one of 8 that started in 2016, is one of 32 in phase 3, and was the 82nd registered.
233 studies on the registry are indexed under Rosacea; 23 are open to participants now.
Browse Rosacea studies →8 of the 145 studies in Rosacea with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Bulgaria, Canada and 6 more countries
Ages 18+
Brigham and Women's Hospital · Sites in United States
Ages 18+
Narrows Institute for Biomedical Research · Sites in United States
Ages 18+ · Healthy volunteers
University of Miami · Sites in United States
Ages 18+
Wright State University · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Rosacea studies recruiting now, 9 (53%) set no upper age limit and 7 (41%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
145 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 44 · Phase 3 34 · Phase 4 20
First in 2002; this study’s year is marked. 8 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 630 is above the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 78 across the 137 interventional studies, 236 across the 8 observational. Of the 127 that completed or were terminated, 76 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 145 have an industry lead sponsor. The 10 most frequent:
This study is registered under Actavis Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Actavis Inc. is the lead sponsor of 95 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 5 studies filed under Rosacea — fewer than ten, so there is no comparison to draw.
3 of the studies in Rosacea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07443202Tarsus Pharmaceuticals, Inc.Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE) | 2026-12-31 |
| NCT06801717University of MiamiRosacea Radiofrequency Microneedling | 2027-07-01 |
| NCT04108897Johns Hopkins UniversityAnalysis of the Microbiome in Rosacea | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 145 studies in Rosacea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized, double-blind, placebo-controlled, parallel-design, multiple-site clinical study to evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (ivermectin) cream 1% (Galderma) in the treatment of moderate to severe papulopustular rosacea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy male or non-pregnant, non-lactating female greater than or equal to 8 years of age with a clinical diagnosis of moderate to severe papulopustular rosacea, defined as the presence of:
A total of 8 to 50 combined papules/pustules on the face, AND At least moderate erythema, AND Telangiectasia
Females of child bearing potential must not be pregnant or lactating at Screening (as confirmed by a negative urine pregnancy test with a sensitivity of less than 25 mlU/mL or equivalent units of human chorionic gonadotropin). Women of must agree to the use of a reliable method of (e.g., total abstinence, IUD, a double-barrier method [such as condom plus diaphragm with spermicide], oral, transdermal, injected or implanted non- or hormonal contraceptive), throughout the study. If the female is using a hormonal contraceptive, the same product must be taken for 3 months prior to Visit 1 and must agree not to replace with some other hormonal contraceptives during the study. A sterile sexual partner is not considered an adequate form of birth control.
All females will be considered to be of childbearing potential unless they: Are , defined as women who have been amenorrheic for at least 12 consecutive months, without other known or suspected primary cause.
Have been sterilized surgically or who are otherwise proven sterile (i.e., total hysterectomy, or bilateral oophorectomy) with surgery at least 4 weeks before Screening. Tubal ligation will not be considered a surgically sterile method.
Female patients of childbearing potential are defined as Women without prior hysterectomy of at least 4 weeks, or who have had any evidence of menses in the past 12 months.
Females who have been amenorrhea for more than or equal to 12 months, but the amenorrhea is possibly due to other causes, including prior chemotherapy, anti-estrogens, or ovarian suppression.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
test product, manufactured by Actavis Laboratories UT, Inc.
Drug: Ivermectin Cream, 1%
reference product, manufactured by Galderma Laboratories, L.P.
Drug: Ivermectin Cream, 1%
Placebo, manufactured by Actavis Laboratories UT, Inc.
Drug: Placebo/Vehicle cream
Percent Change From Baseline to Week 12 in the Number of Inflamed (Papules/Pustules) Lesions of Rosacea.
Bioequivalence of the test to reference was considered to have been demonstrated if the 90% confidence interval for the test to reference ratio for the percent change from baseline to Week 12 in the number of inflamed lesion counts was within \[80%, 125%\].
Time frame: Baseline and 12 Weeks
The Percentage of Patients With a Clinical Response of "Success".
The secondary endpoint was the percentage of patients with a clinical response of "success" using the IGE at Week 12. At Visit 1, the IGE had to be 3 or 4 for the patient to be eligible for inclusion.
Time frame: Baseline to Week 12
| Milestone | Ivermectin Cream, 1% | SoolantraTM (Ivermectin) Cream, 1% | Placebo/Vehicle Cream |
|---|---|---|---|
| Started | 259 | 257 | 114 |
| Completed | 236 | 235 | 100 |
| Not completed | 23 | 22 | 14 |
| Withdrew: Adverse event | 1 | 5 | 3 |
| Withdrew: Lost to follow-up | 10 | 7 | 6 |
| Withdrew: Non-comliance with dosing requirements | 0 | 1 | 0 |
| Withdrew: Protocol violation | 2 | 3 | 1 |
| Withdrew: Withdrawal by subject | 10 | 6 | 2 |
| Withdrew: Worsening of symptom & kit error | 0 | 0 | 2 |
Bioequivalence of the test to reference was considered to have been demonstrated if the 90% confidence interval for the test to reference ratio for the percent change from baseline to Week 12 in the number of inflamed lesion counts was within \[80%, 125%\].
| percentage of change from baseline | Ivermectin Cream, 1% | SoolantraTM (Ivermectin) Cream, 1% | Vehicle Cream |
|---|---|---|---|
| Percent Change From Baseline to Week 12 in the Number of Inflamed (Papules/Pustules) Lesions of Rosacea. | -64.87 ± 2.03 | -64.87 ± 2.03 | -55.04 ± 2.92 |
The secondary endpoint was the percentage of patients with a clinical response of "success" using the IGE at Week 12. At Visit 1, the IGE had to be 3 or 4 for the patient to be eligible for inclusion.
| Participants | Ivermectin Cream, 1% | SoolantraTM (Ivermectin) Cream, 1% | Vehicle Cream |
|---|---|---|---|
| The Percentage of Patients With a Clinical Response of "Success". | 117 | 108 | 45 |
Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ivermectin Cream, 1% | 0/259 (0%) | 0/259 (0%) | 18/259 (6.9%) |
| SoolantraTM (Ivermectin) Cream, 1% | 0/257 (0%) | 0/257 (0%) | 24/257 (9.3%) |
| Placebo/Vehicle Cream | 0/114 (0%) | 0/114 (0%) | 14/114 (12.3%) |
| Event | Ivermectin Cream, 1% | SoolantraTM (Ivermectin) Cream, 1% | Placebo/Vehicle Cream |
|---|---|---|---|
| HeadacheNervous system disorders | 2/259 | 3/257 | 2/114 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/259 | 2/257 | 2/114 |
| NasopharyngitisInfections and infestations | 3/259 | 0/257 | 0/114 |
| Application site eczemaGeneral disorders | 0/259 | 0/257 | 1/114 |
| Application site erythemaGeneral disorders | 0/259 | 0/257 | 1/114 |
| Acute sinusitisInfections and infestations | 0/259 | 0/257 | 1/114 |
| BronchitisInfections and infestations | 1/259 | 0/257 | 1/114 |
| PnuemoniaInfections and infestations | 0/259 | 0/257 | 1/114 |
| SinusitisInfections and infestations | 1/259 | 0/257 | 1/114 |
| Upper respiratory tract infectionInfections and infestations | 0/259 | 0/257 | 1/114 |
| Age, Continuous(years) | Ivermectin Cream, 1% | SoolantraTM (Ivermectin) Cream, 1% | Placebo/Vehicle Cream | Total |
|---|---|---|---|---|
| Mean | 51.8 ± 15.4 | 50.3 ± 15.0 | 51.1 ± 14.1 | 51.1 ± 14.8 |
| Sex: Female, Male(Participants) | Ivermectin Cream, 1% | SoolantraTM (Ivermectin) Cream, 1% | Placebo/Vehicle Cream | Total |
|---|---|---|---|---|
| Female | 182 | 182 | 85 | 449 |
| Male | 77 | 75 | 29 | 181 |
| Ethnicity (NIH/OMB)(Participants) | Ivermectin Cream, 1% | SoolantraTM (Ivermectin) Cream, 1% | Placebo/Vehicle Cream | Total |
|---|---|---|---|---|
| Hispanic or Latino | 136 | 133 | 65 | 334 |
| Not Hispanic or Latino | 123 | 124 | 49 | 296 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ivermectin Cream, 1% | SoolantraTM (Ivermectin) Cream, 1% | Placebo/Vehicle Cream | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 0 | 4 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 0 | 2 |
| White | 253 | 253 | 114 | 620 |
| More than one race | 3 | 0 | 0 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2016 to primary completion in Nov 2016, 5 months.
Results were first posted in Jun 2020, 3 years 7 months after primary completion.
Of 17 phase 3 interventional studies under Rosacea, half reached primary completion within 11 months of starting (the median); a quarter within 9 and three quarters within 15. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.